Core Insights - Yingbairui (Hangzhou) Biopharmaceutical Co., Ltd. successfully completed a nearly 200 million yuan Series B financing, led by Beijing Deep Intelligence Technology Co., Ltd. and supported by notable investors [1][2] - The financing reflects strong market recognition of Yingbairui's core technological capabilities and future development potential, providing robust support for its continued focus on innovative cell therapy [1][2] Financing Details - The Series B financing raised nearly 200 million yuan, which will facilitate Yingbairui's clinical research advancement, large-scale production capacity construction, and commercialization efforts [2] - Deep Intelligence, as the strategic lead investor, aims to leverage its AI-driven drug development advantages to enhance Yingbairui's new drug research decision-making and execution efficiency [2] Company Overview - Yingbairui is a leading company in the global NK cell therapy sector, focusing on cutting-edge tumor immunotherapy and innovative drug development for immune-related diseases, chronic diseases, and CNS diseases [2] - The company has developed a competitive product pipeline based on core technologies such as non-viral vectors and non-gene-modified ACC-NK and tiNK, with several core products already entering clinical stages [2] Future Outlook - The successful financing is expected to accelerate Yingbairui's commercialization process and address unmet clinical treatment needs by providing more safe and effective solutions [2] - With the effective utilization of the newly raised funds, Yingbairui will continue to deepen its focus on innovative cell therapy and core technological breakthroughs [2]